X
Mar 30, 2021 11:35 PM (GMT+8) · EqualOcean
Xinlitai announced that the net profit attributable to shareholders of Listed Companies in the first quarter of 2021 is expected to be 141 million yuan to 165 million yuan, with a year-on-year change of - 6.26% to 10.04%. During the reporting period, the performance contribution of innovative products increased, with a significant year-on-year growth of the company's xinlitan, and the maurora? Rapamycin drug-eluting vertebral artery stent system began to be sold; the company's product revenue structure and profit structure are constantly optimized.

This text is a result of machine translation.